

From the INTERNATIONAL PRELIMINARY EXAMINING

SHIN, Dong-In

D.I. International Patent Office 304, Dukam Bldg., 1457-2 Seocho3-dong, Seocho-gu, Seoul 137-867, Republic of Korea

NOTIFICATION OF TRANSMITTAL OF INTERNATIONAL PRELIMINARY **EXAMINATION REPORT**

(PCT Rule 71.1)

Date of mailing (day/month/year)

21 FEBRUARY 2005 (21.02.2005)

IMPORTANT NOTIFICATION

Applicant's or agent's file reference DBT/031001/Y

Priority date (day/months/year)

International application No. PCT/KR2003/002175 International filing date (day/month/year) 17 OCTOBER 2003 (17.10.2003)

17 OCTOBER 2002 (17.10.2002)

Applicant

DIGITAL BIOTECH CO., LTD. et al

- The applicant is hereby notified that International Preliminary Examining Authority transmits here with the international preliminary examination report and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report(but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected office by performing certain acts (filing translations and paying national fees) within 30 month(s) from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details in the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/KR

Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu. Daejeon 302-701, Republic of Korea

original species

Facsimile No. 82-42-472-7140

Authorized officer

COMMISSIONER

Telephone No. 82-42-481-5198

rate of the





PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Artcle 36 and Rule 70)

							
Applicant's or agent's file reference DBT/031001/Y	FOR FIRTHER ACTION Secretification of Transmittation and Tenthinary						
International application No.	International filing date(day/mo	onth/year)	Priority date (day/month	/vear)			
PCT/KR2003/002175	17 OCTOBER 2003 (17	• -	17 OCTOBER 2002 (17	•			
International Patent Classification (IPC			<u> </u>				
IPC7 C07C 335/04, C0			·				
Applicant							
DIGITAL BIOTECH CO., LT	fD. et al		Pa-1	·			
This international preliminary example and is transmitted to the applicant.	xamination report has been prepart according to Article 36	ared by this Inter	mational Preliminary Exan	nining Authority			
2. This REPORT consists of a total	• •						
This report is also accomp	panied by ANNEXES, i.e., sheets	of the descriptio	n, claims and/or drawings	which have been			
	for this report and/or sheets con he Administrative Instructions un		ons made before this Au	thority (see Rule			
These annexes consist of a total			. ,				
3. This report contains indications	rolation to the Callegrain its area		·				
-	letating to the following items:						
·	I X Basis of the report						
II Priority							
III Non-establishment	of opinion with regard to novelty	, inventive step a	nd industrial applicability				
IV Lack of unity of in	vention						
	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability.						
VI Certain documents							
VII Certain defects in t							
VIII Certain observations on the international application							
Date of submission of the demand	Date	of completion of	this report				
16 APRIL 2004 (1	6.04.2004)	07 FEBRUA	RY 2005 (07.02.2005)				
Name and mailing address of the IPEA	1	orized officer					
Korean Intellectual Property 920 Dunsan-dong, Seo-gu, Republic of Korea	ty Office Daejeon 302-701,	KIM, YONG					
Facsimile No. 82-42-472-7140	Tele	phone No. 82-42	2-481-8148	VEII GO			



Inculational aplication No.

PCT/KR2003/002175

I.	Basis	s of the report					
l.	With	regard to the elements of the international application:*					
	X	the international application as originally filed					
		the description:					
		pages, as originally filed					
		pages, filed with the demand					
		pages, filed with the letter of					
		the claims:					
		pages, as originally filed pages, as amended (together with any statment) under Article 19					
		pages, filed with the demand					
		pages, filed with the letter of					
		the drawings:					
		pages, as originally filed					
		pages, filed with the demand pages, filed with the letter of					
		the sequence listing part of the description:					
		pages					
•		pages, as originally fried pages, filed with the demand pages, filed with the letter of					
٠.٠	·	pages, filed with the letter of					
2.	the i	the language, all the elements marked above were available or furnished to this Authority in the language in which international application was filed, unless otherwise indicated under this item. see elements were available or furnished to this Authority in the following language mich is the language of a translation furnished for the purposes of international search (under Rule 23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/					
3.	Wit pre	or 55.3). th regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international liminary examination was carried out on the basis of the sequence listing: contained inthe international application in written form.					
	$\overline{\sqcap}$	filed together with the international application in computer readable form.					
	$\overline{\Box}$	furnished subsequently to this Authority in written form.					
	\equiv	furnished subsequently to this Authority in computer readable form					
		The statement that the subsequently furnished written sequence listing does not go beyond the disc losure in the international applicationas as filed has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.					
4.		The amendments have resulted in the cancellation of: the description, pages the claims, Nos.					
5. _.		This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box(Rule 70.2(c)).**					
*	in thi	acement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to s opinion as "originally filed." and are not annexed to this report since they do not contain amendments (Rules 70.16 10.17).					
**	Any r	replacement sheet containing such amendments must be referred to under item I and annexed to this report.					



International aplication No.

PCT/KR2003/002175

N. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability;
 citations and explanations supporting such statement

Claims	1-18	YES
Claims	None	NO
Claims	9, 10	YES
Claims	1-8, 11-18	МО
Claims	i-18	YES
Claims	None	NO
	Claims Claims Claims Claims	Claims None Claims 9, 10 Claims 1-8, 11-18 Claims 1-18

2. Citations and explanations (Rule 70.7)

Reference is made to the following documents:

D1: WO 02/16318 A1 (28 Feb. 2002) D2: WO 02/16319 A1 (28 Feb. 2002)

The present invention relates to N-hydroxythiourea, N-hydroxyurea and N-hydroxyamide compounds as a vanilloid receptor antagonist and the pharmaceutical compositions comprising the same.

D1 and D2 which are considered to represent the most relevant state of the art, disclose thiourea, urea and amide compounds as a vanilloid receptor antagonist and the pharmaceutical compositions comprising the same.

1. Novelty

N-Hydroxythiourea, N-hydroxyurea and N-hydroxyamide compounds of claims 1 to 10 are novel in that they have thiourea, urea and amide moiety *substituted with the hydroxy group*, whereas the compounds of D1 and D2 have *unsubstituted* thiourea, urea and amide moiety. Since the compositions of claims 11 to 17 are characterized by the novel compounds of claims 1 to 10, the compositions of these claims are also novel. Moreover, a use claim 18 for the compositions is also novel.

Consequently, the subject matter of the present claims 1 to 18 is considered to be novel under PCT Article 33(2)

2. Inventive Step

N-Hydroxythiourea and N-hydroxyurea compounds of the present invention(claims 1 to 8) are structurally very close to the compounds of D1 and D2 in that they have *N-hydroxythiourea* and *N-hydroxyurea* moiety, and the compounds of D1 and D2 have *thiourea* and *urea* moiety. Furthermore, it is not considered that the compounds of claims 1 to 8 show more potent analgesic activity than the compounds of D1 and D2(see Table 9 in the present invention).

Since the compositions and their use of claims 11 to 18 are characterized by the non-inventive compounds of claims 1 to 8, the compositions and their use of these claims also lack inventive step.

Consequently, the subject matter of the present claims 1 to 8 and 11 to 18 lack an inventive step under PCT Article 33(3).

3. Industrial Applicability

There is no reason for denying industrial applicability of this invention. Consequently, claims 1 to 18 appear to meet the requirement of PCT Article 33(4).